Diagnosis and treatment of metastatic and castration resistant prostate cancer became more and more and complex due to the increasing knowledge and understanding of the underlying molecular events and the subsequently deducted innovative medical treatment.
Modern imaging studies in CRPC have become more selective and currently include positron emission tomography, whole body magnetic resonance imaging, immunoscintigraphy besides the traditional studies such as bone scans and computed tomography.
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial
Dr Cora N Sternberg, MD, Daniel Castellano, MD, Prof Gedske Daugaard, MD,The Lancet Neurology, Volume 15, Issue 11, October 2014, Pages 1263–1268
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.
Smith MR, Sweeney CJ, Corn PG, Et alJ Clin Oncol. 2014 Oct 20;32(30):3391-9. Epub 2014 Sep 15.
New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions?
Wilson L, Tang J, Zhong L, Balani G, Gipson G, Xiang P, Yu D, Srinivas S.J Oncol Pharm Pract. 2014 Dec;20(6):417-25. Epub 2013 Nov 14.
Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial
Prof Karim Fizazi, MD, Prof Howard I Scher, MD, Prof Kurt Miller, MD, Et alThe Lancet Oncology, Volume 15, Issue 10, September 2014, Pages 1147–1156
Canonical androstenedione reduction is the predominant source of signaling androgens in hormone-refractory prostate cancer.
Fankhauser M, Tan Y, Macintyre G, Haviv I, Et alClin Cancer Res. 2014 Nov 1;20(21):5547-57. Epub 2014 Apr 25.
About the editors
- Professor Miller has been Chairman and Professor of Urology for the Department of Urology at the Benjamin Franklin Medical Center, Berlin, Germany, since 1993. In 2007 he became Chairman of the Department of Urology for the entire Charité (Campus Benjamin Franklin, Campus Mitte and Campus Virchow Klinikum). With more than 6000 in-patients per year, the Dep. of Urology at the Charité is one the largest urologicals clinics in Europe.
- Prof Axel S. Merseburger is currently Vice Chairman of the Department of Urologic Oncology, as well as Director of the Urologic Oncology Programme at Hannover Medical School, Germany. Professor Merseburger obtained his medical degree from Hannover Medical School in 2002 following a 1-year academic research programme in Washington D.C., USA, where he finished his M.D. thesis.
- Feb 20155Feb 20157E-mail: firstname.lastname@example.org
- Feb 20157Feb 201510Contact: European School of Urology (ESU) Tel.: +31 26 389 0680 Fax: +31 26 389 0674 E-mail: email@example.com